IKKa restoration via EZH2 suppression induces nasopharyngeal carcinoma differentiation

Nature Communications

Volumn 5, Issue , 2014, Pages

  Yan, Min ^a   Zhang, Yan ^a,b   He, Bin ^a   Xiang, Jin ^a   Wang, Zi Feng ^a   Zheng, Fei Meng ^a   Xu, Jie ^a   Chen, Ming Yuan ^a   Zhu, Yu Liang ^c   Wen, Hai Jun ^a   Wan, Xiang Bo ^c   Yue, Cai Feng ^a   Yang, Na ^a   Zhang, Wei ^a   Zhang, Jia Liang ^a   Wang, Jing ^a   Wang, Yang ^b   Li, Lian Hong ^b   Zeng, Yi Xin ^a   Lam, Eric W F ^d   Hung, Mien Chie ^e,f   Liu, Quentin ^a,b   more..

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; I KAPPA B KINASE ALPHA; RETINOIC ACID; TRANSCRIPTION FACTOR EZH2; EZH2 PROTEIN, HUMAN; I KAPPA B KINASE; POLYCOMB REPRESSIVE COMPLEX 2; SMALL INTERFERING RNA;

CANCER; DISEASE TREATMENT; GENE EXPRESSION; PUBLIC HEALTH; RNA; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; EPIGENETICS; FEMALE; GENE OVEREXPRESSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; MALE; MOLECULAR MECHANICS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TRANSCRIPTION TERMINATION; CELL CYCLE; CHROMATIN IMMUNOPRECIPITATION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; NASOPHARYNX TUMOR; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL CYCLE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; EPIGENESIS, GENETIC; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; NASOPHARYNGEAL NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84898813745     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4661     Document Type: Article

References (58)

1. Stone, R. M. et al. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 71, 690-696 (1988).
2. Cunningham, I. et al. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 73, 1116-1122 (1989). (Pubitemid 19107411)
3. Tallman, M. S. et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 100, 4298-4302 (2002). (Pubitemid 36001941)
4. Tallman, M. S. et al. All-trans-retinoic acid in acute promyelocytic leukemia. N. Engl. J. Med. 337, 1021-1028 (1997). (Pubitemid 27430519)
5. Matthay, K. K. et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N. Engl. J. Med. 341, 1165-1173 (1999). (Pubitemid 29480654)
6. Matthay, K. K. et al. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 27, 1007-1013 (2009).
7. Reddy, S. P., Raslan, W. F., Gooneratne, S., Kathuria, S. & Marks, J. E. Prognostic significance of keratinization in nasopharyngeal carcinoma. Am. J. Otolaryngol. 16, 103-108 (1995).
8. Brodeur, G. M. Neuroblastoma: biological insights into a clinical enigma. Nat. Rev. Cancer 3, 203-216 (2003). (Pubitemid 37328872)
9. Wang, Z. Y. & Chen, Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111, 2505-2515 (2008).
10. Hu, Y. et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKalpha subunit of IkappaB kinase. Science 284, 316-320 (1999).
11. Takeda, K. et al. Limb and skin abnormalities in mice lacking IKKalpha. Science 284, 313-316 (1999). (Pubitemid 129523448)
12. Li, Q. et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev. 13, 1322-1328 (1999). (Pubitemid 29250199)
13. Gareus, R. et al. Normal epidermal differentiation but impaired skin-barrier formation upon keratinocyte-restricted IKK1 ablation. Nat. Cell. Biol. 9, 461-469 (2007). (Pubitemid 46511080)
14. Hu, Y. et al. IKKalpha controls formation of the epidermis independently of NF-kappaB. Nature 410, 710-714 (2001). (Pubitemid 32290360)
15. Descargues, P. et al. IKKalpha is a critical coregulator of a Smad4-independent TGFbeta-Smad2/3 signaling pathway that controls keratinocyte differentiation. Proc. Natl Acad. Sci. USA 105, 2487-2492 (2008). (Pubitemid 351520540)
16. Liu, B. et al. IKKalpha is required to maintain skin homeostasis and prevent skin cancer. Cancer Cell 14, 212-225 (2008).
17. Xiao, Z. et al. The pivotal role of IKKa in the development of spontaneous lung squamous cell carcinomas. Cancer cell 23, 527-540 (2013).
18. Liu, B. et al. A critical role for I kappaB kinase alpha in the development of human and mouse squamous cell carcinomas. Proc. Natl Acad. Sci. USA 103, 17202-17207 (2006). (Pubitemid 44788947)
19. Sparmann, A. & van Lohuizen, M. Polycomb silencers control cell fate, development and cancer. Nat. Rev. Cancer 6, 846-856 (2006). (Pubitemid 44629896)
20. Lee, T. I. et al. Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125, 301-313 (2006). (Pubitemid 44313811)
21. Boyer, L. A. et al. Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441, 349-353 (2006). (Pubitemid 44050199)
22. Bracken, A. P., Dietrich, N., Pasini, D., Hansen, K. H. & Helin, K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20, 1123-1136 (2006).
23. Kwong, J. et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8, 131-137 (2002). (Pubitemid 34101468)
24. Sing, A. et al. A vertebrate Polycomb response element governs segmentation of the posterior hindbrain. Cell 138, 885-897 (2009).
25. Croonquist, P. A. & Van Ness, B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24, 6269-6280 (2005). (Pubitemid 43080050)
26. Cedar, H. & Bergman, Y. Linking DNA methylation and histone modification: patterns and paradigms. Nat. Rev. Genet. 10, 295-304 (2009).
27. Wei, Y. et al. CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat. Cell Biol. 13, 87-94 (2010).
28. Wu, S. & Zhang, Y. Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J. Biol. Chem. 286, 28511-28519 (2011).
29. Ikebe, D., Wang, B., Suzuki, H. & Kato, M. Suppression of keratinocyte stratification by a dominant negative JunB mutant without blocking cell proliferation. Genes Cells. 12, 197-207 (2007). (Pubitemid 46152658)
30. Li, J. T. & Zong, Y. S. A study on the relation of the dysplastic epithelial hyperplasia and squamous metaplasia to the histogenesis of nasopharyneal carcinoma (NPC). Journal of Sun Yat-sen University (Medical Sciences) 6, 21 (1985).
31. Stosiek, P., Kasper, M. & Moll, R. Changes in cytokeratin expression accompany squamous metaplasia of the human respiratory epithelium. Virchows Arch. A Pathol. Anat. Histopathol. 421, 133-141 (1992).
32. van Dorst, E. B., van Muijen, G. N., Litvinov, S. V. & Fleuren, G. J. The limited difference between keratin patterns of squamous cell carcinomas and adenocarcinomas is explicable by both cell lineage and state of differentiation of tumour cells. J. Clin. Pathol. 51, 679-684 (1998). (Pubitemid 28423728)
33. Gigi-Leitner, O., Geiger, B., Levy, R. & Czernobilsky, B. Cytokeratin expression in squamous metaplasia of the human uterine cervix. Differentiation 31, 191-205 (1986). (Pubitemid 17172336)
34. Smedts, F., Ramaekers, F. C. & Vooijs, P. G. The dynamics of keratin expression in malignant transformation of cervical epithelium: a review. Obstet. Gynecol. 82, 465 (1993).
35. Blobel, G. A., Moll, R., Franke, W. W. & Vogt-Moykopf, I. Cytokeratins in normal lung and lung carcinomas. I. Adenocarcinomas, squamous cell carcinomas and cultured cell lines. Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol. 45, 407-429 (1984).
36. Watt, F. M. Involucrin and other markers of keratinocyte terminal differentiation. J. Invest. Dermatol. 81, 100s-103s (1983). (Pubitemid 13030423)
37. Banks-Schlegel, S. & Green, H. Involucrin synthesis and tissue assembly by keratinocytes in natural and cultured human epithelia. J. Cell Biol. 90, 732-737 (1981). (Pubitemid 12254931)
38. Nagle, R. B., Moll, R.,Weidauer, H., Nemetschek, H. & Franke, W. W. Different patterns of cytokeratin expression in the normal epithelia of the upper respiratory tract. Differentiation 30, 130-140 (1985). (Pubitemid 16153848)
39. Huang, W. G. et al. Targeted proteomic analysis of 14-3-3sigma in nasopharyngeal carcinoma. Int. J. Biochem. Cell Biol. 42, 137-147 (2010).
40. Caulin, C., Scholl, F. G., Frontelo, P., Gamallo, C. & Quintanilla, M. Chronic exposure of cultured transformed mouse epidermal cells to transforming growth factor-beta 1 induces an epithelial-mesenchymal transdifferentiation and a spindle tumoral phenotype. Cell Growth Differ. 6, 1027-1035 (1995).
41. Sil, A. K., Maeda, S., Sano, Y., Roop, D. R. & Karin, M. IkappaB kinase-alpha acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 428, 660-664 (2004). (Pubitemid 38524809)
42. Li, T. et al. MicroRNAs modulate the noncanonical transcription factor NF-kappaB pathway by regulating expression of the kinase IKKalpha during macrophage differentiation. Nat. Immunol. 11, 799-805 (2010).
43. Zhu, S. et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting TAB2, TAB3 and IKK-alpha. Nat. Med. 18, 1077-1086 (2012).
44. Marinari, B. et al. IKKalpha is a p63 transcriptional target involved in the pathogenesis of ectodermal dysplasias. J. Invest. Dermatol. 129, 60-69 (2009).
45. Candi, E. et al. p63 is upstream of IKK alpha in epidermal development. J. Cell Sci. 119, 4617-4622 (2006). (Pubitemid 44964258)
46. Maeda, G., Chiba, T., Kawashiri, S., Satoh, T. & Imai, K. Epigenetic inactivation of IkappaB Kinase-alpha in oral carcinomas and tumor progression. Clin. Cancer Res. 13, 5041-5047 (2007). (Pubitemid 47505179)
47. Park, E. et al. Reduction in IkappaB kinase alpha expression promotes the development of skin papillomas and carcinomas. Cancer Res. 67, 9158-9168 (2007). (Pubitemid 47535902)
48. Marinari, B. et al. The tumor suppressor activity of IKKalpha in stratified epithelia is exerted in part via the TGF-beta antiproliferative pathway. Proc. Natl Acad. Sci. USA 105, 17091-17096 (2008).
49. Van Waes, C., Yu, M., Nottingham, L. & Karin, M. Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin. Cancer Res. 13, 4956-4959 (2007). (Pubitemid 47502058)
50. Hung, S. H., Lee, F. P., Su, C. H. & Tseng, H. Effect of all-trans retinoic acid on the growth of two nasopharyngeal cancer cell lines and its treatment potential in combination with cisplatin. Eur. Arch. Otorhinolaryngol. 270, 695-704 (2013).
51. Kwong, J. et al. Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. Int. J. Cancer 113, 386-392 (2005). (Pubitemid 40038705)
52. Licht, J. D. Reconstructing a disease: what essential features of the retinoic acid receptor fusion oncoproteins generate acute promyelocytic leukemia? Cancer Cell 9, 73-74 (2006). (Pubitemid 43202656)
53. Chambon, P. A decade of molecular biology of retinoic acid receptors. FASEB J. 10, 940-954 (1996). (Pubitemid 26285969)
54. Villa, R. et al. Role of the polycomb repressive complex 2 in acute promyelocytic leukemia. Cancer Cell 11, 513-525 (2007). (Pubitemid 46863505)
55. Juan, A. H., Kumar, R. M., Marx, J. G., Young, R. A. & Sartorelli, V. Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol. Cell 36, 61-74 (2009).
56. Alajez, N. M. et al. Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death. Dis. 1, e85 (2010).
57. Wan, X. B. et al. Inhibition of Aurora-A suppresses epithelial- mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 29, 1930-1937 (2008).
58. Hallahan, A. R. et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat. Med. 9, 1033-1038 (2003). (Pubitemid 37021783)